Anlon Healthcare IPO, a Gujarat-based pharmaceutical ingredients manufacturer, is launching its Initial Public Offering (IPO) from August 26 to August 29, 2025, priced between ₹86 and ₹91 per share. This maiden issue is a fresh equity offering of 1.33 crore shares, aiming to raise approximately ₹121 crore, with no offer-for-sale component. Post-listing, the company’s market capitalization is expected to reach around ₹484 crore. Investor allocations are structured as 75% for qualified institutional buyers (QIBs), 15% for non-institutional investors (NIIs), and 10% for retail investors, with a lot size of 164 shares, requiring a minimum investment of about ₹14,924. The anchor book opens on August 25, and the basis of allotment is scheduled for September 1, followed by refunds and share credits on September 2, and listing on both major exchanges on September 3.

Proceeds from the IPO will be used for expanding the manufacturing facility (₹30.7 crore), working capital needs (₹43.15 crore), repayment of existing debt, and other general corporate purposes. Anlon Healthcare specializes in manufacturing high-purity pharmaceutical intermediates and active pharmaceutical ingredients (APIs), adhering to stringent national and international pharmacopeia standards. In FY2024, the company posted revenue of ₹66.6 crore and net profit of ₹9.65 crore, compared to ₹112.9 crore revenue and ₹5.82 crore profit in FY2023. For the 10 months ending January 2025, revenue improved to ₹77.2 crore with profit near ₹12 crore. The Anlon Healthcare IPO represents a timely opportunity to back a quality-focused player in the growing pharma ingredients sector.